Related Experiment Videos
CA 125 and CA 19-9 immunolocalization in normal, hyperplastic, and carcinomatous endometrium
E Podczaski1, P F Kaminski, R Zaino
1Department of Obstetrics and Gynecology, Pennsylvania State University School of Medicine, Hershey Medical Center, Hershey 17033.
Cancer
|April 15, 1993
Summary
This study investigated CA 125 and CA 19-9 expression in endometrial tissues. Endometrial carcinomas frequently express these tumor-associated antigens, with expression correlating to tumor characteristics.
Area of Science:
- Gynecologic Oncology
- Tumor Immunology
- Biomarker Discovery
Background:
- Elevated tumor-associated antigens like CA 125 are observed in endometrial carcinoma.
- This study examines the prevalence and distribution of CA 125 and CA 19-9 in normal and cancerous endometrium.
Purpose of the Study:
- To evaluate the frequency and tissue distribution of CA 125 and CA 19-9 in normal and neoplastic endometrium.
- To understand the relationship between antigen expression and clinicopathological features of endometrial cancer.
Main Methods:
- Immunohistochemistry was used to assess CA 125 and CA 19-9 expression on endometrial tissue sections.
- The avidin-biotin technique was employed to visualize antibody-antigen binding.
Main Results:
- CA 125 expression in normal endometrium varied with the menstrual cycle, peaking in the secretory phase.
- CA 125 was detected in 68% of endometrial carcinomas, while CA 19-9 was found in 60%.
- Antigen expression showed concordance in 76% of evaluated tumors and related to tumor grade and cell type.
Conclusions:
- CA 125 is uniformly expressed in normal endometrial glandular cells.
- CA 19-9 expression in normal endometrium may be linked to the Lewis A phenotype.
- Endometrial carcinomas commonly express CA 125 and CA 19-9, with expression levels tied to tumor characteristics.